Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (4045)	3/10/2006 8:39:27 AM
From: dr.praveen	Respond to of 12215

Keryx commences phase II trial in leukemia 3rd March 2006 By Staff Writer <Rick, one to watch apart from the promising MPC6827> Keryx Biopharmaceuticals has initiated a phase II, multi-center, clinical program to evaluate its investigational anticancer compound KRX-0401 as a treatment for leukemia. Advertisement This clinical trial will assess the objective response rate and evaluate the pharmacokinetics and safety and tolerability of KRX-0401 (perifosine) as a single agent in relapsed or refractory acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), high-risk myelodysplastic syndrome (MDS) and chronic myeloid leukemia in the blastic phase. KRX-0401 is a novel, first-in-class, oral anticancer agent that modulates AKT and a number of other key signal transduction pathways, including the MAPK and JNK pathways. The compound has shown single agent partial responses or long-term disease stabilizations in solid tumors, including sarcoma and prostate cancer. "There is an increasing focus on inhibition of the AKT pathway as a potentially rewarding anti-leukemia approach. The clinical and preclinical data gathered on this study will help to assess AKT as a potential target, and will tell us if perifosine is useful for these patients, who desperately need an improvement over current therapies," Dr Frank Giles the principal investigator for the study, and a professor at the department of leukemia at the MD Anderson Cancer Center in Houston.